Parkinson disease: From the neuroinflammation to neuroprotection


on the April 9, 2019

Collaborative research project led by Prof. Gaillard A (LNEC, INSERM U1084, Université de Poitiers, France) to which Dr. Sylvie Chalon participated

Inflammatory process in Parkinson disease: neuroprotection by neuropeptide Y


Parkinson's disease (PD) is characterized by the degeneration of dopaminergic neurons in the nigro-striatal pathway. Interestingly, it has already been shown that an intracerebral administration of neuropeptide Y (NPY) decreases the neurodegeneration induced by 6-hydroxydopamine (6-OHDA) in rodents and prevents loss of dopamine (DA) and DA transporter density. The etiology of idiopathic PD now suggest that chronic production of inflammatory mediators by activated microglial cells mediates the majority of DA-neuronal tissue destruction. In an animal experimental model of PD, the present study shows that NPY inhibited the activation of microglia evaluated by the binding of the translocator protein (TSPO) ligand [3H]PK11195 in striatum and substantia nigra of 6-OHDA rats. These results suggest a potential role for inflammation in the pathophysiology of the disease and a potential treatment by NPY in PD.

© 2019 Société Française de Pharmacologie et de Thérapeutique.


#Parkinson disease #inflammation #neuropeptide Y #neuroprotection

Contact :
Dr. Sylvie Chalon :